Registry for BRCA Mutation Carriers with Pancreatic Ductal Adenocarcinoma

Inclusion Criteria

• BRCA mutation carrier is defined as a person with any mutation of the BRCA gene, including BRCA1, or BRCA2. PALB2mut patients are also eligible
• Relative of a BRCA PDAC patient is defined as a first-degree or second-degree relative, which includes parents, siblings, children, grandparents, grandchildren, aunts, uncles, nephews, nieces and half-siblings
• Participants in Control Cohort 5 are people of AJ descent who are first-degree or second degree relatives of an AJ descent non-BRCAmut patient with PDAC
• A Multiplex family is defined as one in which there are at least two first or second degree relatives with PDAC
• STUDY GROUP A: Known BRCA mutation carrier
• STUDY GROUP A: Ashkenazi Jewish descent (at least one parent of Ashkenazi Jewish origin)
• STUDY GROUP A: Histologic proof of primary pancreatic ductal adenocarcinoma
• STUDY GROUP A: May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC
• STUDY GROUP A: Prior personal history of other malignancy; either prior or currently active, including breast, ovarian, or prostate cancer is allowed
• STUDY GROUP A: Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy
• STUDY GROUP A: Willing to provide blood specimens for correlative studies
• STUDY GROUP A: Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry
• STUDY GROUP B: Known BRCA mutation carrier
• STUDY GROUP B: Histologic proof of primary pancreatic ductal adenocarcinoma
• STUDY GROUP B: May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC
• STUDY GROUP B: Prior personal history of other malignancy; either prior or currently active, including breast, ovarian, or prostate cancer is allowed
• STUDY GROUP B: Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy
• STUDY GROUP B: Willing to provide blood specimens for correlative studies
• STUDY GROUP B: Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry
• COHORT 1A: Known BRCA mutation carrier
• COHORT 1A: Ashkenazi Jewish descent (at least one parent of Ashkenazi Jewish origin)
• COHORT 1A: No current or prior history of PDAC
• COHORT 1A: First or second degree relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer
• COHORT 1A: Willing to provide blood specimens for correlative studies
• COHORT 1B: Known BRCA mutation carrier
• COHORT 1B: No current or prior history of PDAC
• COHORT 1B: First or second degree relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer
• COHORT 1B: Willing to provide blood specimens for correlative studies
• COHORT 2A: Known BRCA mutation carrier
• COHORT 2A: Ashkenazi Jewish descent (at least one parent of Ashkenazi Jewish origin)
• COHORT 2A: No current or prior history of PDAC
• COHORT 2A: First or second degree relative of a BRCAmut PDAC patient
• COHORT 2A: Prior or active personal history of any BRCA-related cancer
• COHORT 2A: Willing to provide blood specimens for correlative studies
• COHORT 2B: Known BRCA mutation carrier
• COHORT 2B: No current or prior history of PDAC
• COHORT 2B: First or second degree relative of a BRCAmut PDAC patient
• COHORT 2B: Prior or active personal history of any BRCA-related cancer
• COHORT 2B: Willing to provide blood specimens for correlative studies
• COHORT 3A: Known BRCAmut carrier
• COHORT 3A: Ashkenazi Jewish decent (at least one parent of Ashkenazi Jewish origin)
• COHORT 3A: No current or prior personal history of PDAC
• COHORT 3A: Prior personal history of other malignancy including breast, ovarian, or prostate cancer is allowed
• COHORT 3A: Willing to provide blood specimens for correlative studies
• COHORT 3B: Known BRCAmut carrier
• COHORT 3B: No current or prior personal history of PDAC
• COHORT 3B: Prior personal history of other malignancy including breast, ovarian, or prostate cancer is allowed
• COHORT 3B: Willing to provide blood specimens for correlative studies
• COHORT 4: Tested for and negative for the BRCA founder mutations
• COHORT 4: Ashkenazi Jewish descent (at least one parent of Ashkenazi Jewish origin)
• COHORT 4: Not related to known BRCAmut carrier
• COHORT 4: Histologic proof of primary pancreatic ductal adenocarcinoma. May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC
• COHORT 4: Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy
• COHORT 4A: Willing to provide blood specimens for correlative studies
• COHORT 4: Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the registry
• COHORT 5: Tested for and negative for the BRCA founder mutations
• COHORT 5: Ashkenazi Jewish decent (at least one parent of Ashkenazi Jewish origin)
• COHORT 5: No current or prior personal history of PDAC
• COHORT 5: Prior personal history of other malignancy including breast, ovarian, or prostate cancer is allowed
• COHORT 5: First or second degree relative of a Control-Cohort 4 participant from a multiplex PDAC family
• COHORT 5: Willing to provide blood specimens for correlative studies

Exclusion Criteria

• Are unable to sign informed consent for medical or other reasons
• Do not speak English (Memorial Sloan Kettering [MSK]) or do not speak English or Hebrew (BCGC Sites)
• Are under 21 years of age
• Not willing to provide blood samples for correlative studies